Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best method to cut blood loss in fibroid surgery

NCT ID NCT07526311

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two surgical techniques to reduce blood loss during open fibroid removal. Forty women with symptomatic uterine fibroids will be randomly assigned to either bilateral uterine artery ligation or a pericervical mechanical tourniquet. The goal is to see which method causes less bleeding and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If one technique proves better, it could help surgeons reduce bleeding during fibroid removal, making the surgery safer.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply to everyone. Both techniques are surgical procedures with inherent risks like infection or injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 48 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: * Female participants aged 25 to 48 years * Body mass index less than 35 kg/m² * Symptomatic uterine myomas requiring surgical treatment * Intramural myomas classified as FIGO types 3 to 6 * Diagnosis confirmed by transvaginal ultrasound and/or magnetic resonance imaging * Maximum diameter of the largest myoma 20 cm or less * Scheduled for elective transabdominal myomectomy * Able and willing to provide written informed consent * Exclusion Criteria: * Submucosal, intracavitary, pedunculated subserosal, cervical, or adnexal myomas * FIGO types 0, 1, 2, 7, or 8 myomas * History of pelvic inflammatory disease or peritonitis * Previous abdominal or pelvic surgery for non-obstetric causes * Previous uterine surgery * Use of hormonal therapy within the previous 3 months * Known bleeding disorder * Use of anticoagulant or antiplatelet therapy * Preoperative hemoglobin less than 10 g/dL * Body mass index 35 kg/m² or greater * Intraoperative conversion from myomectomy to hysterectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage myofibroma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood loss Myoma;uterus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cairo University

    RECRUITING

    Cairo, Al-Manial, 11956, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.